KRAS and lung carcinoma: A previous study showed that concurrent KRAS and TP53 mutations in lung cancer are accompanied by high CD8 + T-cell infiltration and PD-L1 levels, suggesting that these patients are candidates for αPD-L1 immune checkpoint blockade60.